Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon

被引：0

作者：

Schuette, W. ^{[1
]}

Thomas, M. ^{[2
]}

Eberhardt, W. ^{[3
]}

Zirrgiebel, U. ^{[4
]}

Radke, S. ^{[5
]}

Dietel, M. ^{[6
]}

机构：

[1] Krankenhaus Martha Maria, Halle, Saale, Germany

[2] Univ Klinikum, Thoraxklin, Heidelberg, Germany

[3] Univ Klinikum, Med Onkol, Essen, Germany

[4] iOMEDICO AG, Freiburg, Germany

[5] AstraZeneca GmbH, Wedel, Germany

[6] Humboldt Univ, Pathol Inst, D-10099 Berlin, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0341

引用

页码：120 / 120

页数：1

共 41 条

[11] High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
Lee, S. H.
Sung, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S932
[12] High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
Sung, Ji-Youn
Park, Dong-Won
Lee, Seung-Hyeun
BIOMEDICINES, 2022, 10 (09)
[13] High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy.
Lee, Seung Hyeun
Sung, Ji-Youn
CANCER RESEARCH, 2021, 81 (13)
[14] Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis
Ma, Ji-Yong
Yan, Hai-Jun
Gu, Wei
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 397 - 402
[15] Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial.
Schuette, Wolfgang
Behlendorf, Timo
Schirmacher, Peter
Eberhardt, Wilfried
Dietel, Manfred
Zirrgiebel, Ute
Muehlenhoff, Lars
Thomas, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[16] Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
Cai, Boning
Li, Xiaomo
Huang, Xiang
Ma, Tonghui
Qu, Baolin
Yu, Wei
Yang, Wei
Zhang, Pei
Chen, Jing
Liu, Fang
FRONTIERS IN ONCOLOGY, 2021, 11
[17] Clinical-Pathological and Survival Analysis of Patients with Advanced NSCLC and EGFR Mutation Treated With a Drug Therapy Anti-T790M
Corral, Jesus
Cervera, Antonio
Maiquez, Pilar
Alonso, Miriam
Dolores Mediano, Maria
Jose Flor, Maria
Jimenez, Lucia
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S411
[18] Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
Zhou, Jiawei
Bai, Jianling
Yue, Yuanping
Chen, Xin
Lange, Theis
You, Dongfang
Zhao, Yang
FRONTIERS IN ONCOLOGY, 2022, 11
[19] Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy
Yuxin Zhao
Haiyong Wang
Chengwei He
Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3653 - 3664
[20] Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy
Zhao, Yuxin
Wang, Haiyong
He, Chengwei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3653 - 3664

← 1 2 3 4 5 →